Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group..

Neurology. 2010 Dec 7;75(23):2087-96. doi: 10.1212/WNL.0b013e318200d727.

2.

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC.

Neurology. 2011 Apr 19;76(16):1403-9. doi: 10.1212/WNL.0b013e31821670fb.

PMID:
21502598
3.

HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.

Kelly CM, van Oosterhout JJ, Ngwalo C, Stewart RC, Benjamin L, Robertson KR, Khoo S, Allain TJ, Solomon T.

PLoS One. 2014 Jun 10;9(6):e98962. doi: 10.1371/journal.pone.0098962. eCollection 2014 Jun 10.

4.

Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.

Cysique LA, Brew BJ.

J Neurovirol. 2011 Apr;17(2):176-83. doi: 10.1007/s13365-011-0021-x. Epub 2011 Mar 17.

PMID:
21416169
5.

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group.; HNRC Group..

J Neurovirol. 2011 Feb;17(1):3-16. doi: 10.1007/s13365-010-0006-1. Epub 2010 Dec 21.

6.

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.

Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I; CHARTER Group..

AIDS. 2011 Sep 10;25(14):1747-51. doi: 10.1097/QAD.0b013e32834a40cd.

7.

Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.

Kallianpur AR, Wang Q, Jia P, Hulgan T, Zhao Z, Letendre SL, Ellis RJ, Heaton RK, Franklin DR, Barnholtz-Sloan J, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Grant I; CHARTER Study Group..

J Infect Dis. 2016 Apr 1;213(7):1065-73. doi: 10.1093/infdis/jiv754. Epub 2015 Dec 21.

PMID:
26690344
8.

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.

Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ.

Neurology. 2009 Aug 4;73(5):342-8. doi: 10.1212/WNL.0b013e3181ab2b3b. Epub 2009 May 27.

9.

Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.

Nichols SL, Bethel J, Garvie PA, Patton DE, Thornton S, Kapogiannis BG, Ren W, Major-Wilson H, Puga A, Woods SP.

J Adolesc Health. 2013 Dec;53(6):763-71. doi: 10.1016/j.jadohealth.2013.07.006. Epub 2013 Aug 21.

10.

Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.

Evering TH, Applebaum A, La Mar M, Garmon D, Dorfman D, Markowitz M.

AIDS. 2016 Jan;30(2):203-10. doi: 10.1097/QAD.0000000000000892.

11.

Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.

Garvey L, Surendrakumar V, Winston A.

HIV Clin Trials. 2011 Nov-Dec;12(6):333-8. doi: 10.1310/hct1206-333.

PMID:
22189152
12.

Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders.

Morgan EE, Woods SP, Letendre SL, Franklin DR, Bloss C, Goate A, Heaton RK, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Ellis RJ, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Grant I, Vaida F, Clifford DB; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group..

J Neurovirol. 2013 Apr;19(2):150-6. doi: 10.1007/s13365-013-0152-3. Epub 2013 Feb 14.

13.

Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Cysique LA, Brew BJ.

Neuropsychol Rev. 2009 Jun;19(2):169-85. doi: 10.1007/s11065-009-9092-3. Epub 2009 May 9. Review.

PMID:
19424802
14.

Cognitive disorders in HIV-infected patients: are they HIV-related?

Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy FA, Mercié P, Greib C, Richert L, Neau D, Catheline G, Dehail P, Dabis F, Morlat P, Dartigues JF, Chêne G; S CO3 Aquitaine Cohort..

AIDS. 2013 Jan 28;27(3):391-400. doi: 10.1097/QAD.0b013e32835b1019.

PMID:
23079813
15.

Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.

Lawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, Nthobatsang R, Steenhoff A.

J Int AIDS Soc. 2010 Apr 20;13:15. doi: 10.1186/1758-2652-13-15.

16.

Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals.

Suh HS, Lo Y, Choi N, Letendre S, Lee SC.

J Neuroinflammation. 2015 Apr 15;12:72. doi: 10.1186/s12974-015-0288-6.

17.

Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men.

McDonnell J, Haddow L, Daskalopoulou M, Lampe F, Speakman A, Gilson R, Phillips A, Sherr L, Wayal S, Harrison J, Antinori A, Maruff P, Schembri A, Johnson M, Collins S, Rodger A; Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group..

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):120-7. doi: 10.1097/QAI.0000000000000273.

18.

Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.

Shanbhag MC, Rutstein RM, Zaoutis T, Zhao H, Chao D, Radcliffe J.

Arch Pediatr Adolesc Med. 2005 Jul;159(7):651-6.

PMID:
15996999
19.

Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings.

Cherner M, Ellis RJ, Lazzaretto D, Young C, Mindt MR, Atkinson JH, Grant I, Heaton RK; HIV Neurobehavioral Research Center Group..

AIDS. 2004 Jan 1;18 Suppl 1:S27-34.

PMID:
15075495
20.

The prevalence and incidence of neurocognitive impairment in the HAART era.

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ.

AIDS. 2007 Sep 12;21(14):1915-21.

PMID:
17721099

Supplemental Content

Support Center